IFITM3 rs12252-C variant increases potential risk for severe influenza virus infection in Chinese population

Frontiers in Cellular and Infection Microbiology

Volumn 7, Issue JUN, 2017, Pages

  Pan, Yang ^a,b,c   Yang, Peng ^a,b,c   Dong, Tao ^d   Zhang, Yi ^a,b   Shi, Weixian ^a,b   Peng, Xiaomin ^a,b   Cui, Shujuan ^a,b   Zhang, Daitao ^a,b   Lu, Guilan ^a,b   Liu, Yimeng ^a,b   Wu, Shuangsheng ^a,b   Wang, Quanyi ^a,b,c  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Beijing Research Center for Preventive Medicine   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Genetic susceptibility; Influenza; Interferon inducible transmembrane 3; Severe acute respiratory infection; Single nucleotide polymorphism

Indexed keywords

CHEMOKINE; INTERFERON INDUCIBLE TRANSMEMBRANE 3 PROTEIN; UNCLASSIFIED DRUG; IFITM3 PROTEIN, HUMAN; MEMBRANE PROTEIN; RNA BINDING PROTEIN;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; FLU LIKE SYNDROME; GENDER; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; IFITM3 GENE; INFECTION RISK; INFLUENZA; INFLUENZA A; INFLUENZA A VIRUS (H1N1) 09PDM; INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA B VIRUS (VICTORIA); INFLUENZA B VIRUS (YAMAGATA); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; REAL TIME POLYMERASE CHAIN REACTION; RECESSIVE GENE; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; ADOLESCENT; AGED; CHINA; COMMUNICABLE DISEASE; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GENOTYPE; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MIDDLE AGED; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRUS INFECTION; PATHOGENICITY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHINA; COMMUNICABLE DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPIRATORY TRACT INFECTIONS; RNA-BINDING PROTEINS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85027544878     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2017.00294     Document Type: Article

References (21)

1. Abecasis, G. R., Auton, A., Brooks, L. D., DePristo, M. A., Durbin, R. M., Handsaker, R. E., et al. (2012). An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65. doi: 10.1038/nature11632
2. Bailey, C. C., Huang, I. C., Kam, C., and Farzan, M. (2012). Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 8:e1002909. doi: 10.1371/journal.ppat.1002909
3. Brass, A. L., Huang, I. C., Benita, Y., John, S. P., Krishnan, M. N., Feeley, E. M., et al. (2009). The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139, 1243–1254. doi: 10.1016/j.cell.2009.12.017
4. Chinese National Influenza Center (2012). Influenza Surveillance Program for Mainland China, 2010. Beijing: Chinese National Influenza Center.
5. Compton, A. A., Roy, N., Porrot, F., Billet, A., Casartelli, N., Yount, J. S., et al. (2016). Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity. EMBO Rep. 17, 1657–1671 doi: 10.15252/embr.201642771
6. Dunning, J., Baillie, J. K., Cao, B., and Hayden, F. G. (2014). Antiviral combinations for severe influenza. Lancet Infect. Dis. 14, 1259–1270. doi: 10.1016/S1473-3099(14)70821-7
7. Everitt, A. R., Clare, S., Pertel, T., John, S. P., Wash, R. S., Smith, S. E., et al. (2012). IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484, 519–523. doi: 10.1038/nature10921
8. Gaio, V., Nunes, B., Pechirra, P., Conde, P., Guiomar, R., Dias, C. M., et al. (2016). Hospitalization risk due to respiratory illness associated with genetic variation at IFITM3 in patients with influenza A(H1N1)pdm09 infection: a case-control study. PLoS ONE 11:e0158181. doi: 10.1371/journal.pone.0158181
9. Hayward, A. C., Fragaszy, E. B., Bermingham, A., Wang, L., Copas, A., Edmunds, W. J., et al. (2014). Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med. 2, 445–454. doi: 10.1016/S2213-2600(14)70034-7
10. Lopez-Rodriguez, M., Herrera-Ramos, E., Sole-Violan, J., Ruiz-Hernandez, J. J., Borderias, L., Horcajada, J. P., et al. (2016). IFITM3 and severe influenza virus infection. No evidence of genetic association. Eur. J. Clin. Microbiol. Infect. Dis. 35, 1811–1817. doi: 10.1007/s10096-016-2732-7
11. Matias, G., Taylor, R. J., Haguinet, F., Schuck-Paim, C., Lustig, R. L., and Fleming, D. M. (2016). Modelling estimates of age-specific influenza-related hospitalisation and mortality in the United Kingdom. BMC Public Health 16:481. doi: 10.1186/s12889-016-3128-4
12. Mills, T. C., Rautanen, A., Elliott, K. S., Parks, T., Naranbhai, V., Ieven, M. M., et al. (2014). IFITM3 and susceptibility to respiratory viral infections in the community. J. Infect. Dis. 209, 1028–1031. doi: 10.1093/infdis/jit468
13. Perreira, J. M., Chin, C. R., Feeley, E. M., and Brass, A. L. (2013). IFITMs restrict the replication of multiple pathogenic viruses. J. Mol. Biol. 425, 4937–4955. doi: 10.1016/j.jmb.2013.09.024
14. Rohlfs, R. V., and Weir, B. S. (2008). Distributions of Hardy-Weinberg equilibrium test statistics. Genetics 180, 1609–1616. doi: 10.1534/genetics.108.088005
15. Smith, S., Weston, S., Kellam, P., and Marsh, M. (2014). IFITM proteins-cellular inhibitors of viral entry. Curr. Opin. Virol. 4, 71–77. doi: 10.1016/j.coviro.2013.11.004
16. Sun, X., Zeng, H., Kumar, A., Belser, J. A., Maines, T. R., and Tumpey, T. M. (2016). Constitutively expressed IFITM3 protein in human endothelial cells poses an early infection block to human influenza viruses. J. Virol. 90, 11157–11167. doi: 10.1128/JVI.01254-16
17. Thomas, R. E. (2014). Is influenza-like illness a useful concept and an appropriate test of influenza vaccine effectiveness? Vaccine 32, 2143–2149. doi: 10.1016/j.vaccine.2014.02.059
18. Wang, Z., Zhang, A., Wan, Y., Liu, X., Qiu, C., Xi, X., et al. (2014). Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc. Natl. Acad. Sci. U.S.A. 111, 769–774. doi: 10.1073/pnas.1321748111
19. Williams, D. E., Wu, W. L., Grotefend, C. R., Radic, V., Chung, C., Chung, Y. H., et al. (2014). IFITM3 polymorphism rs12252-C restricts influenza A viruses. PLoS ONE 9:e110096. doi: 10.1371/journal.pone.0110096
20. World Health Organization (2014). WHO Global Epidemiological Surveillance Standards for Influenza. Geneva: WHO.
21. Zhang, Y.-H., Zhao, Y., Li, N., Peng, Y.-C., Giannoulatou, E., Jin, R.-H., et al. (2013). Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat. Commun. 4:1418. doi: 10.1038/ncomms2433